Table 1.
Platform | resolution | TAT(days) | Alterations | Analytical method | Advantage | Disadvantage | Ref |
---|---|---|---|---|---|---|---|
Karyotyping | 5~10 Mb | 2~21 | CNV, SV | Qualitative | A gold standard | Highly dependent on the expertise of technicians and cytogeneticists | [59] |
FISH | 80–200 kb | 3~5 | CNV, SV | Qualitative | A gold standard that serves as a means of verification of known tumor sites | Expensive, customization limited by the types of genomic variation, depending on subjective assessment | [37,38] |
CMA | 20–100 kb | 3~14 | CNV, LOH | Quantitative | Cost-effective, significant advantages in detecting genomic variations greater than 100 Kb, | Limited by the types of genomic variation and the use of hybridization-based assays in repeat-rich and duplicated regions | [40,60,61] |
CNV-seq | ~100 kb | 5~14 | CNV, SV, LOH, SNV, Indel | Quantitative | High throughput, excellent compatibility, enabling the detection of large fragments of CNVs at a whole-genome scale. | Cannot detect ROH | [62] |
WGS | ≥1 bp | 5~14 | CNV, SV, LOH, SNV, Indel | Quantitative | High throughput, comprehensive evaluation of all tumor variation information | Expensive, long turnaround time, heavy computational requirements | [63] |
WES | ≥1 bp | 5~14 | CNV, SV, LOH, SNV, Indel | Quantitative | High throughput, cost-efficient, and analytic-effective manner | Cannot detect pathogenic CNVs located within non-coding regions associated with human disease | [64] |
dPCR | ≥1 bp | 2~5 | CNV, SV, LOH, SNV, Indel | Absolute quantification | Higher accuracy and reproducibility | Limited or biased by a probe design | [65,66] |
Abbreviations: CNV, copy number variations; SV, structural variants; FISH, fluorescence in situ hybridization; CMA, CNV microarrays; LOH, loss of heterozygosity; ROH, runs of homozygosity; SNV, single nucleotide variants; WGS,whole genomic sequencing; WES, whole exome sequencing; dRCR, droplet PCR.